Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis

Psoriatic Arthritis Clinical Trial

— PATERA  

Official title:

An International Multicenter Randomized Double-blind Placebo-controlled Clinical Study of the Efficacy and Safety of Subcutaneous BCD-085 in Patients With Psoriatic Arthritis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03598751
• Other study ID #: BCD-085-8
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: July 25, 2018
• Est. completion date: November 2022

Study information

• Verified date: September 2021
• Source: Biocad
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study BCD-085-8/PATERA is a multicentre double-blind placebo-controlled Phase 3 study in patients with psoriatic arthritis (PsA). The objective of the study is to evaluate the efficacy and safety of BCD-085 comparing to placebo in patients with PsA.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 194
• Est. completion date: November 2022
• Est. primary completion date: June 26, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent (IC)

• History of psoriatic arthritis (According to CASPAR, 2006) for 6 months

• 3/68 TJC and 3/66 SJC

• RF / ACCP negative

• At least 1 psoriatic plaque = 2 cm and/or psoriatic nails and/or history of confirmed plaque psoriasis

• History of inadequate response to NSAID

• Stable dose of NSAID for 2 weeks

• If on steroids: inadequate response to steroids (at least 3 months of treatment) and stable dose of steroids (10 mg or less) for at least 2 weeks.

• If on MTX: inadequate response to MTX (stable dose 15 - 25 mg / week for at least 2 months)

• In case of history of etanercept therapy: at least 4 weeks after last administration

• In case of history of infliximab therapy: at least 8 weeks after last administration

• In case of history of adalimumab / golimumab / certolizumab pegol therapy: at least 10 weeks after last administration

• In case of history of other mabs / fragments / small molecules : at least 5 half life after last administration

• Negative pregnancy test for women with childbearing potential

• Ability to follow procedures of the study

• Patient and his/her sexual partner with childbearing potential are ready to use reliable contraception, starting at the date of IC sign, within the study period and 4 weeks after the last dose of investigational drug administration. (Not applied to participants/sexual partners who surgically sterilized, and women at menopause for more than 2 years). Reliable contraception considered as 1 barrier method and one of the following: spermicides, oral contraception or intrauterine devices)

Exclusion Criteria:

• Therapy with anti-IL17 / IL17R or anti-IL12/23 or history of therapy with 2 or more monoclonal antibodies or therapy with topical / oral retinoids or phototherapy or other topical medication for psoriasis history or parenteral steroids administration or any intraarticular injections within 4 weeks prior IC sign or any DMARD therapy (excl. methotrexate) on the dated of IC

• Vaccination with live vaccines within 8 weeks prior to IC sign

• Diagnosis of any other chronic infection which may increase the risk of infectious adverse events.

• HIV, HCV, HBV, Syphilis.

• Clinically significant deviations in blood chemistry and blood count

• History of Herpes Zoster

• History of depression, suicidal ideation/behavior.

• Known history of alcohol or drug abuse

• Diagnosis or history of tuberculosis

• Any acute infection or chronic infection flare within 30 days prior to informed consent sign, which may increase (according to the PI opinion) the risk of infectious adverse events.

• Any other documented conditions which increase the risk of AEs development or may interfere with symptoms the disease (masking, increasing or changing) or induce clinical symptoms or laboratory abnormalities similar to PsA:

1. Uncontrolled diabetes mellitus;

2. Severe, uncontrolled hypertension;

3. Presence or history of inflammatory joint disease other than PsA (or any other systemic autoimmune disease (including lupus, Crohn's disease, ulcerative colitis, scleroderma, inflammatory myopathy, mixed connective tissue disease, autoimmune overlap syndrome, fibromyalgia etc.);

4. History of malignancy, excluding cured basal cell carcinoma / cervical cancer in situ (complete remission for 5 years); cured basal cell skin carcinoma (5 years complete remission), cured ductal breast cancer (5 years complete remission);

5. Decompensated liver or kidney diseases;

6. Unstable angina pectoris;

7. Chronic heart failure, class III-IV according to NYHA;

8. Myocardial infarction, within 1 year prior to IC sign;

9. History of organ transplantation;

10. History of Quincke edema;

11. History of any significant respiratory diseases, including COPD, asthma or bronchiectasis;

12. Decompensated respiratory failure;

13. History of multiple sclerosis,

14. Devic's disease, or Guillain-Barre syndrome;

15. Any neurological disease with motor or sensory functions impairment)

• Pregnancy, current or planned in less than 8 weeks after study completion or breastfeeding.

• Simultaneous participation in other clinical trials or participation in other clinical trials with 3 month prior to IC signing date or history of participation it current clinical study (excluding patients dropped out at screening).

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Psoriatic
• Psoriatic Arthritis

Intervention

Drug:
• BCD-085
120 mg / 2 mL subcutaneously
• Placebo
2 mL

Locations

Country	Name	City	State
Belarus	1st City Clinical Hospital	Minsk
Russian Federation	Chelyabinsk Regional Clinical hospital	Chelyabinsk
Russian Federation	North-Western State Medical University n.a. I.I.Mechnikov	Saint-Petersburg

Sponsors (1)

Lead Sponsor	Collaborator
Biocad

Countries where clinical trial is conducted

Belarus,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ACR 20	The percentage of patients achieved 20% improvement according to American College of Rheumatology response criteria.; The ACR Criteria is a dichotomous variable with a positive (=responder) or negative (=non-responder) outcome. The ACR Criteria measures improvement in tender / swollen joint counts and improvement in at least three of the following parameters: 1) patient assessment 2) physician assessment 3) pain scale 4) disability/functional questionnaire 5) acute phase reactant (ESR or CRP). ACR 20 / 50 / 70 has a positive outcome if 20% / 50% / 70% improvement in tender and swollen joint counts was achieved as well as a 20% / 50% / 70% improvement in at least three of the other five criteria.	week 24
Secondary	ACR 20	The percentage of patients achieved 20% improvement according to American College of Rheumatology response criteria.	Week 1, 2, 4, 8, 12, 16, 20, 24, 30, 38, 46, 54
Secondary	ACR 50	The percentage of patients achieved 50% improvement according to American College of Rheumatology response criteria.	Week 1, 2, 4, 8, 12, 16, 20, 24, 30, 38, 46, 54
Secondary	ACR 70	The percentage of patients achieved 70% improvement according to American College of Rheumatology response criteria.	Week 1, 2, 4, 8, 12, 16, 20, 24, 30, 38, 46, 54
Secondary	Proportion of patients achieved PsARC (Psoriatic Arthritis Response Criteria)		Week 1, 2, 4, 8, 12, 16, 20, 24, 30, 38, 46, 54
Secondary	Change in radiological signs of arthritis (mTSS)	mTSS - modified Total Sharp Score	Week 24 and 54
Secondary	Proportion of patients with anti-drug antibodies		Week 2, Week 12, Week 24, Week 38, Week 54